WIHS Hepatitis Working group summary
Introduction
Hepatitis C virus (HCV) co-infection is common in HIV-seropositive patients due to shared routes of viral transmission [1] . Compared with patients infected with HCV alone, individuals co-infected with HCV and HIV have accelerated liver disease progression [2, 3] . Women with HCV have less liver disease progression than men [4] . With HIV-seropositive patients now living longer through use of HAART, HCV-related hepatic fibrosis and cirrhosis has become a major health problem. Liver disease is currently the leading cause of non-AIDS related death among HCV/HIV-co-infected patients [5] .
Little is known about the predictors of mortality in HCV/ HIV-co-infected individuals, and most of the data have been obtained in men [6, 7] . As HCV-mono-infected women generally have a less aggressive course of liver disease than men, separate studies of women and men are necessary [4] . Assessment of liver disease severity, most notably the degree of hepatic fibrosis, is critical to guide treatment and prognostic counseling. Currently, liver biopsy is the gold standard for determining the degree of hepatic fibrosis; however, liver biopsy is also an invasive and costly procedure. Therefore, substantial efforts have been focused on the identification of noninvasive serum markers that are not only useful for identifying fibrosis among patients with chronic liver disease but are also easily obtained in the clinical setting. Two fibrosis marker scoring systems, the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) [8] and FIB-4 index [based upon age, AST, alanine aminotransferase (ALT) level and platelet count] [9] , have been developed. The aim of the current investigation was to assess the value of APRI and FIB-4 as markers of survival outcome among a large cohort of HCV/HIV-co-infected women. We chose these two markers as they are based upon readily available, routine laboratory tests and have been shown to be useful for predicting significant fibrosis among patients with HCV.
Materials and methods

Patient population
An analysis of clinical and laboratory parameters was performed in women enrolled in the Women's Interagency HIV Study (WIHS). The details of this prospective, multicenter, longitudinal cohort study have been published [10] . Briefly, the WIHS enrolled 3 766 adult women in two cohorts (1994-1995 and 2001-2002) at six clinical sites across the United States who were either infected with HIV or at high risk for acquiring HIV. Overall, 32% of HIV-seropositive women were co-infected with HCV, acquired prior to enrolment in WIHS. Only 17 (1.8%) women received therapy for HCV. Overall participant retention and study follow-up was 82% as described [11] . All women gave written, informed consent for participation in WIHS. The WIHS study was approved by all Institutional Review Boards of the participating medical centers, and this study was reviewed and approved by the University of California San Francisco Institutional Review Board.
Because the advent of HAART fundamentally changed the natural history of HIV, this analysis was restricted to HCV/HIV-co-infected women on HAART. The first visit on HAART with available data for APRI and FIB-4 assessment is referred to as the index visit. In order to focus on chronic liver disease and minimize the possibility of including women with acute hepatic inflammation and severe thrombocytopenia resulting from causes other than HCV-related cirrhosis, we excluded study visits with AST or ALT greater than 10 times upper limit of normal (ULN) and platelet counts less than 25 000 Â 10 6 cells/l. Only women with at least one follow-up visit after the index visit with laboratory and clinical values for calculation of APRI (AST and platelet count) and FIB-4 (AST, ALT, platelet count and age) were included in this study. Because of the limited number of women (n ¼ 42) under 35 years of age at entry into WIHS, we included only those women who were at least 35 years of age at the index visit.
Data collection
Every 6 months, participants undergo a comprehensive physical examination, provide biological specimens for CD4 cell count and HIV-RNA viral load determination, and complete an interviewer-administered questionnaire that collects information on demographics, health history and medication use. Data on current alcohol usage were derived from a standardized questionnaire and categorized as light (<3 drinks/week), moderate (3-13 drinks/ week) or heavy (>13 drinks per week) as well as number of drink per year over the time of the study. Intravenous drug use was also documented at each clinical visit. Hepatitis B virus status was assessed via testing for the surface antigen (HBsAg) within the first year of entry into WIHS. HCV infection was documented by testing for antibody to HCV by second-generation or thirdgeneration enzyme linked immunoassay (Ortho-Diagnostic Systems, Rochester, New York, USA) and testing for the presence of HCV-RNA by HCV-branched DNA (Quantiplex 2.0 branched chain DNA-enhanced label amplification assay; Bayer-Versant Diagnostics, formerly Chiron Diagnostics, Emeryville, California, USA) and by reverse transcriptase polymerase chain reaction (COBAS Amplicor HCV Detection Kit, Roche Diagnostic Systems, Pleasanton, California, USA). HIV-RNA was measured using the isothermal nucleic acid sequencebased amplification (NASBA/Nuclisens) method (bioMerieaux, Durham, North Carolina, USA) with a detection limit of 80 copies/ml.
The definition of HAART was based on the US Department of Health and Human Services (DHHS) treatment guidelines (www.aidsinfo.gov) as use of more than two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with at least one protease inhibitor or one non-NRTI (NNRTI); one NRTI in combination with at least one protease inhibitor and at least one NNRTI; or an abacavir-containing or tenofovir-containing regimen of more than three NRTIs in the absence of both protease inhibitors and NNRTIs, except for the three NRTI regimens consisting of abacavir with tenofovir and lamivudine or didanosine with tenofovir and lamivudine.
Assessment of liver fibrosis
Two indirect markers of liver fibrosis were used for this analysis: APRI [8] and FIB-4 [9] with ALT ULN designated as 40 U/l. These measures can be calculated using readily available patient and laboratory data [AST, ALT, platelet count (Â 10 9 cells/l) and age] according to the equations given below:
APRI ¼ ðAST=upper limit of ASTÞ Â 100 platelet count ð10 9 =LÞ FIB À 4 ¼ age ðyearÞ Â AST platelet count ð10 9 =lÞ Â ALT
1=2
Assessment of mortality outcome
The primary outcome of interest for these analyses was all-cause mortality. A secondary outcome was cause of death, categorized as liver-related or nonliver-related, based on death certificate reporting of primary cause of death [12] . In order to detect all deaths among WIHS participants, a number of active and passive ascertainment methods were employed. Death certificates were obtained from medical records and local health departments as soon as the study staff became aware of a death. To assure that all deaths in the United States were ascertained, National Death Index (NDI)-Plus searches were performed annually for all WIHS participants who were known to have died or were lost to study follow-up. The NDI-Plus provides information on deaths that occur throughout the United States and US territories and provides all the primary and underlying causes from the original death certificates. All death certificate data were reviewed independently by two clinicians using specific criteria that classified a death as AIDS-related if an AIDSdefining infection or malignancy was the cause of death, or if the cause of death was pneumonia or sepsis in the setting of a recent CD4 þ cell counts less than 200 cells/ml. Deaths were classified as indeterminate if the cause of death was entirely nonspecific (most frequently 'cardiopulmonary arrest'), if the death certificate had conflicting causes or had HIV as the only cause of death for a woman whose CD4 þ cell count was at least 200 cells/ml at the most recent WIHS visit. Deaths were classified as non-AIDS if a non-AIDS cause was the primary cause of death. Patients were followed up until death, the end of the follow-up period in December 2007 or until the last completed study visit.
Statistical analysis
Continuous data were summarized using median and interquartile range (IQR), and categorical variables were summarized using frequency and percentage. The role of APRI and FIB-4 fibrosis markers as predictors of all-cause mortality was assessed using semiparametric Cox proportional hazard regression, after adjusting for known predictors of post-HAART mortality, including pre-HAART peak HIV viral load (copies/ml), pre-HAART nadir CD4 count (cells/ml) and evidence of clinical AIDS pre-HAART. Pre-HAART nadir CD4 was a categorical variable based upon CD4 cut-points (<100, 100-200, 200-350, >350 cells/ml). Specifically, different models were constructed for APRI and FIB-4 in which each fibrosis marker was expressed as either a continuous (logtransformed) or categorical (mild, moderate, severe) variable. APRI and FIB-4 marker levels were treated as time-dependent with the most current (last available) used for these analyses. The cut-points used to categorize fibrosis severity were derived from previous studies of these markers and were as follows: APRI (<0.5 mild, 0.5-1.5 moderate, >1.5 severe) and FIB-4 (<1.5 mild, 1.5-3.25 moderate, >3.25 severe) [8, 9] . As the date of HCV infection was unknown, and the risk of mortality is fundamentally associated with age, we utilized age as the timescale for the analysis in conjunction with left truncation (staggered entry) methods. Individuals contributed at-risk time to the analysis beginning at their age at the index visit.
In addition to modeling all-cause mortality, deaths were also classified as liver-related and nonliver-related for the subgroup of women who had at least two fibrosis marker measurements within the 5 years prior to death. Although the total number of liver-related deaths was not sufficient for a multivariate survival analysis (n ¼ 27), longitudinal profiles of APRI and FIB-4 marker levels were compared among women with liver-related and nonliver-related deaths. For these analyses, linear random effects regression modeling was conducted to compare the liver-related and nonliver-related death groups, with time measured as years from death, and log 10 transformation of fibrosis marker levels to make the data approximately normally distributed. To account for any nonlinearity, the model also included a smooth trend with time, which was allowed to vary between the liver-related and nonliverrelated death groups. To estimate trends, spline models were utilized [13] . All data analyses were performed using SAS (SAS Institute Inc., Cary, North Carolina, USA) and S-Plus (Insightful Corp., Seattle, Washington, USA).
Results
Patient population
There were 450 HCV/HIV-co-infected women over 35 years of age who had at least one liver fibrosis marker (APRI or FIB-4) measurement post-HAART initiation (Table 1) . Of these, 191 women died during follow-up. The characteristics of the study population at index visit, including those who died and those who survived are shown in Table 1 . The median age of the women at index visit was 43 years (IQR 40-47 years). Two-thirds (62%) of the participants were non-Hispanic black (n ¼ 281) and 20% (n ¼ 92) were Hispanic. The majority of women reported abstinence from alcohol at their index visit; however, 18% were moderate-to-heavy drinkers. Only 17 (1.8) % of women were treated for HCV and 5% had diabetes. The 450 women included in these analyses participated in a total of 5739 WIHS visits. Median follow-up time was 6.6 years (IQR 3.2-9.8 years).
Aspartate aminotransferase-to-platelet ratio index and FIB-4 and all-cause mortality Table 2 shows the association of APRI and FIB-4 at the last available visit with all-cause mortality in HCV/HIVco-infected women receiving HAART, using Cox proportional hazard regression models. Of the 450 HCV/HIV-co-infected women in Table 1 , relevant covariates and adequate follow-up in the WIHS study beyond the date of their initial fibrosis marker measurements were available in 422, of whom 186 were known to have died. Analysis of all-cause mortality was performed in these 422 women. Data are expressed as hazard ratios and their associated 95% confidence intervals (95% CI). We first developed a 'null' model that included HIV-related covariates known to be related to all-cause mortality, including pre-HAART nadir and current CD4 cell counts, log 10 pre-HAART peak and current HIV viral load and clinical AIDS pre-HAART. Among these, current CD4 cell counts less than 200 cells/ml and current HIV viral load were significantly associated with all-cause mortality. Addition of APRI or FIB-4 to the model demonstrated that these liver fibrosis markers were independent and significant predictors of all-cause mortality ( Table 2) . When modeled as a categorical variable, APRI marker levels more than 1.5 (severe fibrosis) were significantly associated with an increased risk of all-cause mortality (hazard ratio 2.78, 95%CI 1.87-4.12), compared with women with low APRI (<0.5, mild fibrosis) levels. Furthermore, women categorized with FIB-4 marker levels more than 3.25 (severe fibrosis) had significantly increased risk of allcause mortality, compared with women with low FIB-4 (<1.5) levels (hazard ratio 2.58, 95% CI, 1.68-3.95). For the categorical expressions of APRI and FIB-4, only the highest of the three fibrosis levels (severe fibrosis) was significantly associated with increased all-cause mortality ( Table 2) .
When modeled as a continuous variable (Table 2b) , an increase in the APRI marker level of 0.25 from the median index visit APRI level of 0.59 was associated with age at death as a predictor, indicated age was not significant for either APRI (P ¼ 0.07) or FIB-4 (P ¼ 0.29), so this effect was removed from the final model. For both APRI and FIB-4, the difference between the smooth trends for liver-related versus nonliver-related deaths was highly significant (P < 0.001 for both markers). The longitudinal analysis demonstrated that both APRI and FIB-4 fibrosis marker measurements increased during the 5 years prior to death for all women; however, the slope of the increase was greater for women who died a liver-related death compared with nonliver-related death. For APRI, the estimated slopes (adjusting for nonlinear curvature) were À0.0142 (P ¼ 0.94) for nonliver-related death and 1.201 (P ¼ 0.025) for liver-related death. For FIB-4, the estimated slopes were 0.042 (P ¼ 0.78) for nonliver-related death and 0.837 for liver-related death (P ¼ 0.054). In both the APRI and FIB-4 models, the nonlinear trends were significantly different between the two death groups (both P ¼ 0.024). In addition, APRI and FIB-4 fibrosis marker levels were higher at all time points during the 5 years prior to death in women who died a liver-related death (Figs 1 and 2 lower panel), compared with women whose cause of death was nonliver-related (Figs 1 and 2 upper panel) (P ¼ 0.001 for APRI and FIB-4).
Discussion
This study showed that FIB-4 and APRI were strongly associated with all-cause mortality in HCV/HIV-co- Although liver biopsy is considered by clinicians to be the most useful method to determine the amount of hepatic fibrosis and inflammation, it is an imperfect test, providing a small piece of liver with nonuniform histologic findings. Smaller tissue samples generally underestimate fibrosis [14] [15] [16] [17] . In WIHS, only 20% of HCV/HIV-co-infected women have undergone liver biopsy and fewer (1.8%) have received therapy for HCV.
WIHS is not a treatment study, but an observational cohort. However, women are encouraged to seek treatment for HCV by WIHS investigators and we have provided educational programs, so that participants can learn about their HCV, liver disease and possible therapies.
In light of these limitations of liver biopsy, there has been interest and progress made in the development of noninvasive markers of hepatic fibrosis. One of these indices, FIB-4, was developed and validated in a cohort of patients co-infected with HCV/HIV [9] . This study found that FIB-4 had an accuracy of 0.77 for differentiating between Ishak fibrosis stage 0-3 and Ishak fibrosis stage 4-6 among patients co-infected with HCV/HIV [18] . APRI has been demonstrated to predict significant fibrosis and cirrhosis, with accuracies of 0.80 and 0.89, respectively, in patients with HCV infection alone [8] and somewhat decreased accuracy (0.71-0.73 for cirrhosis) in the co-infected populations [19] [20] [21] . The serological noninvasive methods of fibrosis assessment can be performed on small volume blood samples and can be automated and repeated frequently and retrospectively. Other markers of mortality risk include the model for end-stage liver disease [22] and Child-Pugh-Turcotte scores [23] . In patients with known cirrhosis (F4) and decompensated liver disease, they have been used to assess mortality risk for surgery and need for liver transplantation. They are not used in patients without cirrhosis in contrast to APRI and FIB-4, which assess the amount of liver fibrosis from none (F0) to cirrhosis (F4).
Death certificates have certain limitations and those 'nonliver deaths' in HCV/HIV-co-infected women may have had significant contribution from liver disease: for example, the contribution of hepatic disease may not have been noted in septic deaths, renal deaths and multisystem organ failure [12] . In addition, not all abnormalities leading to changes in ALT, AST and platelets can be assumed to be due to hepatic fibrosis progression per se, as hematologic disorders and medication effects, likely more common in HIV, may cause changes. As noted above, WIHS is an observational study without patient visits, so we do not have data for APRI or FIB-4 in hospitalized women or women who missed visits. Of interest, there were higher rates of death in women with severe fibrosis scores, suggesting that liver fibrosis played a role even in women deemed to have died from HIV. Indeed, our results demonstrate a significant association between increased levels of APRI and FIB-4 and the risk of death from any cause. Other studies have shown that HCV/ HIV co-infection is associated with higher mortality than HIV alone [5] . APRI and FIB-4 do not distinguish the cause of fibrosis. Patients with HCV have increased hepatotoxicity from HAART [24] , and those with cirrhosis have altered metabolism of drugs.
Our study is the first longitudinal study of noninvasive markers of fibrosis solely in women co-infected with HCV and HIV. The fibrosis markers were predictive of all-cause mortality, but were abnormal some years before death and were higher in women dying a liver-related death. This suggests that these noninvasive markers can be of practical value in all women co-infected with HIV and HCV to determine whether liver disease is progressing and, if so, to reinforce the need for therapy for HCV. These noninvasive markers have been shown to predict liver-related death in a smaller cohort of HIV-infected individuals, predominantly men [25] . During the 5 years prior to death, our data showed higher overall fibrosis marker (APRI and FIB-4) levels, as well as more rapid increases in fibrosis marker levels in women who experienced a liver-related death compared with women who experienced a nonliver-related death. As the components of these indirect fibrosis tests are readily available as part of clinical care, they can be used to assess progression of liver fibrosis and even risk of mortality in co-infected women. This may lead patients and their providers to more strongly consider HCV therapy. Better, noninvasive methods for assessment of liver fibrosis are needed to provide timely selection of women whose liver disease is progressing and who are, therefore, in more urgent need of therapy for HCV.
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Introduction
In the United States, at least 5 million people are infected with hepatitis C, 80 % of whom are estimated to be viremic [1, 2] . Due to shared modes of transmission, HCV infection in patients with HIV infection is common. Approximately one-third of HIV infected patients are co-infected with HCV, and this number approaches 80 % in the intravenous (IV) drug using community [3] . Clearance of HCV avoids progression of liver disease and its related complications, which are typically more severe in co-infected patients than in HCV mono-infection. HIV/HCV co-infected patients have higher baseline HCV RNA levels and higher liverrelated mortality, with faster rates of liver fibrosis. Most pertinent to this study, fewer patients with HIV and acute HCV spontaneously clear the virus as compared to those without HIV infection [4] [5] [6] [7] . Gender differences in spontaneous HCV clearance in HCV mono-infection are well documented, with higher spontaneous clearance in women compared to men [8] [9] [10] . However, few studies have examined factors associated with spontaneous HCV clearance in HIV infected women. Studies among predominantly HCV mono-infected men have shown that race is an important predictor of spontaneous HCV clearance, with African Americans having lower spontaneous HCV clearance than Caucasians. No studies in either HIV infected or uninfected cohorts have characterized spontaneous HCV clearance in Hispanic individuals as compared to African Americans [11] [12] [13] . Data investigating racial/ethnic differences in spontaneous HCV clearance in women are also limited, and even fewer studies have investigated these trends in HIV infected women.
In the present study, we evaluate racial/ethnic differences in spontaneous HCV clearance and report factors associated with spontaneous HCV clearance in a large population of HIV infected, HCV seropositive women and a smaller sample of HIV uninfected women from the Women's Interagency HIV Study (WIHS). The diversity of the WIHS, which includes a large proportion of Hispanic and African American women, has allowed us to study the effect of race/ethnicity on the natural history of hepatitis C in this high risk female cohort.
Methods
Data Source
We conducted a cross sectional study of women participating in the WIHS. The WIHS is an NIH funded, prospective, multicenter US cohort of women at risk for, or currently diagnosed with HIV. The WIHS is comprised of women with high risk behaviors, with most women having a history of illicit drug use. Enrollment in WIHS occurred in two study cohorts, the first in 1994-1995 and the second in 2001-2002 [14] . Women in WIHS are seen twice yearly and undergo detailed histories, physical exams, structured interviews, and laboratory testing. Serum samples from these visits are stored for future analyses. This study was approved by the WIHS research committee and the Institutional Review Boards (IRB) at the six participating WIHS study sites.
Study Sample
The present study included all women with prior infection with hepatitis C as defined by positive HCV antibody at entry into WIHS. HIV was confirmed by positive Western blot. All eligible women were at least 18 years old at WIHS study entry. Women who had received prior treatment for hepatitis C of any duration were excluded.
Predictor and Outcome Measures
The primary predictor was race/ethnicity determined by self-report at WIHS entry visit. We defined the ''African American'' group as non Hispanic African Americans. The ''Caucasian'' group was defined as non Hispanic Caucasians. The ''Hispanic'' group was defined as Hispanic Caucasians, Hispanic African Americans, and other Hispanics. The small number of women who self-reported as Asian, Pacific Islander, Native American, Alaskan or ''other'' were classified as ''Other.'' To evaluate the possibility of misclassification bias, all analyses were repeated after recategorizing Hispanic African Americans as African American, and also after recategorizing Hispanic Caucasians as Caucasian.
The outcome measure was presence or absence of HCV RNA by PCR at WIHS entry as the indicator of persistent or cleared HCV infection, respectively. HCV RNA was tested on 86.2 % of women at subsequent follow-up visits and [98 % were confirmed positive. The following characteristics were taken from WIHS entry: age, history of alcohol use, hepatitis B viral (HBV) status [hepatitis B surface antigen (HBsAg) and core antibody (HBcAb)], HIV RNA, CD4 count, and mode of possible HCV infection as measured by number of sexual partners, history of blood transfusion, and history of intravenous drug use (IVDU). Alcohol use was defined as C14 drinks per week. Blood transfusion history was defined as receipt of a transfusion before 1985, the year when donated blood became routinely screened for HIV.
Laboratory Assays
Plasma HIV RNA levels were measured using the NASBA/ NuciSens HIV RNA assay (bioMerieux, Durham, NC) in laboratories certified by the NIH National Institute of Allergy and Infectious Diseases Virology Quality Assurance Certification Program. HCV and HBV serologies were performed using standard commercial assays and included hepatitis C antibody by EIA 3.0 (Ortho-Clinical Diagnostics, Raritan, NJ), hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), and hepatitis B core antibody (anti-HBc) (Abbott Laboratories, Abbott Park, IL). HCV RNA was measured in HCV seropositive women, using either the COBAS Amplicor Monitor 2.0 assay (Roche Diagnostics, Branchburg, NJ) with a linear range of 600-700,000 IU/ml or COBAS Taqman (Roche Diagnostics), with a linear range of 10-2.0 9 10 8 IU/ml. Of the HIV infected women, 60.9 % were African American, 19.3 % Hispanic, 17.7 % Caucasian, and 2.1 % ''other.'' Compared to women with spontaneous HCV clearance, women with chronic infection had lower median CD4 counts, higher median HIV RNA levels, and a lower prevalence of chronic hepatitis B. The majority of women with chronic hepatitis C were infected with genotype 1 (Table 1 ). There were clear differences in spontaneous HCV clearance across racial/ethnic groups of HIV infected women (test for homogeneity, p = 0.023). On multivariate analysis among HIV infected women, African Americans were less likely to have spontaneously cleared HCV than Caucasians (OR 0.57, 95 % CI 0.36-0.93, p = 0.023) or Hispanics (OR 0.59, 95 % CI 0.38-0.93, p = 0.022). Spontaneous HCV clearance was similar between HIV infected Hispanic and Caucasian women ( Table 2) . These trends remained consistent after recategorizing African American Hispanics as African American, and also after recategorizing Hispanic Caucasians as Caucasian (see Supplementary Materials).
In the HIV infected cohort the presence of chronic hepatitis B was strongly associated with spontaneous HCV clearance on univariate analysis (OR 3.0, 95 % CI 1.40-6.2, p = 0.004). The magnitude of association was stronger after adjusting for age, race/ethnicity, alcohol use, CD4 count and HIV viral load (OR 3.5, 95 % CI 1.57-7.9, p = 0.002). Higher HIV RNA levels were inversely associated with HCV clearance on both univariate (OR 0.73, 95 % CI 0.62-0.85, p \ 0.0001) and multivariate analyses (OR 0.75, 95 % CI 0.61-0.92, p = 0.006). There was a statistically significant association between spontaneous HCV clearance and higher CD4 count on univariate (OR 1.19, 95 % CI 1.05-1.34, p = 0.006) but not on multivariate analysis (OR 1.07, 95 % CI 0.93-1.24, p = 0.324). Age, alcohol use, and presumed mode of HCV transmission were not significantly associated with spontaneous HCV clearance, but age and alcohol were maintained in the final model due to strong biologically plausible effects on spontaneous HCV clearance (Table 3) . We also analyzed spontaneous HCV clearance in the subset of HIV uninfected women in WIHS (n = 171). Their racial/ethnic distribution was 52.1 % African American, 27.5 % Hispanic, 17.5 % Caucasian, and 2.9 % ''other'' (Table 4 ). Significant differences in spontaneous HCV clearance across racial/ethnic groups were observed (test for homogeneity, p = 0.0022), similar to those observed in HIV infected women. On multivariate analysis, African Americans were less likely to have spontaneously cleared HCV than Caucasians (OR 0.26, 95 % CI 0.09-0.79, p = 0.017) or Hispanic women (OR 0.18, 0.07-0.48, p = 0.001). These findings also remained consistent after recategorizing African American Hispanics as African American, and after recategorizing Hispanic Caucasians as Caucasian (see Supplementary Materials). No additional factors were associated with spontaneous HCV clearance in the HIV uninfected population (Table 5) .
Discussion
In this large population of HIV infected women with prior exposure to hepatitis C, we investigated racial/ethnic differences in spontaneous HCV clearance and identified additional factors associated with spontaneous HCV clearance. We also investigated racial/ethnic trends in spontaneous HCV clearance in a smaller group of HIV uninfected women in WIHS. We found that compared to Caucasian and Hispanic women, African Americans were less likely to spontaneously clear HCV, regardless of HIV status. Hispanic women appeared similar in spontaneous HCV clearance to Caucasians. Among a comprehensive set of factors with possible biological effects on spontaneous HCV clearance, we found strong evidence that chronic hepatitis B and lower HIV RNA were associated with spontaneous HCV clearance among HIV infected women.
Racial/ethnic differences in spontaneous HCV clearance between African Americans and Caucasians are well documented, particularly among those without HIV infection. Among HIV uninfected individuals, African Americans are less likely to spontaneously clear the virus as compared to Caucasian or Asian patients, with a higher percentage of African Americans developing chronic HCV [10, 12, 13] . Similar trends were observed in a study of 478 HIV Bold text indicates statistical significance a Self-report as Asian, Pacific Islander, Native American, Alaskan Native or ''other'' Dig Dis Sci infected, HCV exposed hemophiliacs which found significantly reduced spontaneous HCV clearance among African Americans compared to non-African Americans [15] . Like most natural history studies, this cohort included only a handful of women (*1 %), although this was one of the first studies to document racial/ethnic differences in spontaneous HCV clearance between Caucasian and African American HIV infected patients. A prior study of HIV infected women in WIHS also found that African-Americans have a higher likelihood of developing chronic HCV infection than Caucasians, with no significant differences between Caucasian and Hispanic women [16] . Our study adds to these findings by investigating spontaneous HCV clearance between African American and Hispanic women. In addition, we expanded HCV RNA testing to all HCV antibody positive women in WIHS; we repeated HCV viral load testing allowing for confirmation of HCV chronicity; and also report HCV genotype distribution among chronically infected women. Finally, in our study we repeated all analyses after re-categorizing racial/ethnic groups to further evaluate for possible misclassification bias, and continued to observe lower HCV clearance in African Americans as compared to Caucasian and Hispanic women.
Although prior studies have documented racial/ethnic differences in HCV fibrosis progression between Hispanics, Caucasians and African Americans, no prior studies have investigated differences in spontaneous HCV clearance between African Americans and Hispanics [17] . As 20 % of our cohort was comprised of Hispanic women, we were able to report these novel results, showing lower spontaneous HCV clearance among African Americans as compared to Hispanics, in both our HIV infected and uninfected cohorts.
The mechanisms underlying these racial/ethnic differences in spontaneous HCV clearance are not fully defined. While it is possible that body mass index, baseline alcohol use, or baseline HCV RNA may account for differences seen among racial/ethnic groups, studies adjusting for these factors, including our study which accounted for a host of potential confounders, continue to observe marked racial/ ethnic differences [18, 19] . Recent data show that immunogenetics explain a large part of spontaneous HCV clearance. A genome-wide association found that a single nucleotide polymorphism (SNP) upstream of the IL28B gene was strongly predictive of spontaneous HCV clearance in HIV uninfected patients [20] . The frequency of this beneficial genotype is higher in Caucasians (39 %) and Hispanics (35 %) as compared to African Americans (16 %) [21] . This explains in part why African Americans have lower spontaneous HCV clearance compared to other racial/ethnic groups. In HIV infected cohorts, two studies have identified additional SNPs in close proximity to the IL28B gene that are strongly associated with spontaneous HCV clearance. As these studies were conducted in homogenous European cohorts, the role of IL28B in explaining racial/ethnic differences in spontaneous HCV clearance among HIV infected individuals has yet to be determined [22, 23] . Genome wide association studies investigating the role of IL28B are currently underway within the WIHS and may help to explain why spontaneous HCV clearance differs so markedly between HIV infected racial/ethnic groups.
Independent of race/ethnicity, we identified lower HIV RNA as an important factor associated with spontaneous HCV clearance. While higher CD4 counts predicted increased clearance on univariate analysis, this finding was not statistically significant on multivariate analysis. Similar to our results, a study of mostly male HIV infected patients with hemophilia found little association between CD4 count and spontaneous HCV clearance. Although these authors found no association between detectable HIV RNA and spontaneous HCV clearance, they did not study the association between the degree of HIV viremia and HCV clearance, which we were able to investigate [15] .
There were several limitations to our present study. Although we used self-report of race/ethnicity as our primary predictor, self-report may not accurately reflect [24] . To reduce possible misclassification of racial/ethnic groups in our study, we did analyze our results after recategorizing Hispanic African Americans as African American, and after recategorizing Hispanic Caucasians as Caucasian. We observed consistently lower spontaneous HCV clearance in African Americans as compared to Caucasians and Hispanics, for all analyses performed. Importantly, previous data suggest that in IV drug users, HCV is often acquired years before HIV, although the temporal association between HIV and HCV viral acquisition in our study cannot be confirmed [25] . HCV re-infection is also possible, although prior data within the WIHS indicate that this is a rare occurrence, at less than 1 % [26] . In summary, we observed significant racial/ethnic differences in spontaneous HCV clearance in a large HIV infected population and a smaller population of HIV uninfected women. In both groups, African American women had significantly lower spontaneous HCV clearance than Hispanic or Caucasian women. Spontaneous HCV clearance in HIV infected women was associated with better HIV immune status, an effect that was independent of race/ethnicity. Immunogenetic studies are currently underway within the WIHS to help explain why spontaneous HCV clearance differs so markedly between racial/ethnic groups. Marek Nowicki, 6 Michael Plankey, 7 Stephen Gange, 8 Gerald Sharp, 9 Howard Minkoff, 10 and Marion G. Peters 1 for the Women's Interagency HIV Study (WIHS)
Among individuals with and without concurrent human immunodeficiency virus (HIV), racial/ethnic differences in the natural history of hepatitis C virus (HCV) have been described. African Americans have lower spontaneous HCV clearance than Caucasians, yet slower rates of liver fibrosis once chronically infected. It is not clear how these differences in the natural history of hepatitis C affect mortality, in either HIV-positive or -negative individuals. We conducted a cohort study of HIV/HCV coinfected women followed in the multicenter Women's Interagency HIV Study to determine the association of self-reported race/ethnicity with all-cause and liver-related mortality. Survival analyses were performed using Cox's proportional hazards models 3 Among patients with HIV, hepatitis C-related liver disease remains the second leading cause of death. 4 Data projecting liver-related mortality also indicate that deaths from hepatitis C are continuing to rise and remain an important cause of premature mortality. [5] [6] [7] Racial/ethnic differences in the natural history of hepatitis C have been well described. Spontaneous HCV clearance is lower among African Americans, compared to Caucasians and Hispanics, yet African Americans appear to develop less fibrosis and inflammation once chronically infected, compared to other racial/ethnic groups. [8] [9] [10] It remains unclear how these racial differences in the natural history of hepatitis C may affect liver-related death, in either HCV monoinfection or in HIV/HCV-coinfected individuals.
Data on race and mortality in patients with chronic HCV infection are conflicting. Several recent studies have reported higher death rates among Caucasians with chronic hepatitis C (CHC), compared to African Americans, although one large study observed opposite trends. [11] [12] [13] [14] Most studies have also focused on male predominant cohorts, with limited available data on race and mortality among women with HCV or HIV/ HCV coinfection.
Given conflicting previous data on race and mortality, and the absence of robust data in either female or HIV-infected populations, we aimed to determine the association between race/ethnicity and liver-related death in a large cohort of HIV/HCV-coinfected women followed in the Women's Interagency HIV Study (WIHS). The rich ethnic diversity and longterm follow-up of WIHS participants has allowed us to address these important racial and ethnic distinctions.
Patients and Methods
Study Population. We conducted a cohort study of women participating in the WIHS. The WIHS is a National Institutes of Health (NIH)-funded, prospective, multicenter cohort of women at risk for, or currently diagnosed with, HIV. Enrollment in the WIHS took place in two study cohorts: the first in 1994-1995 and the second in [2001] [2002] . 15 Women in the WIHS are seen twice-yearly and undergo detailed histories, physical exams, structured interviews, and laboratory testing. This study was approved by the WIHS Executive Committee and the institutional review boards at the six participating WIHS study sites. Study eligibility included HIV/HCV coinfection at WIHS study entry, as defined by detectable HCV RNA, HCV antibody (Ab), and positive HIV western blotting. Because of the small number of women who selfreported as other than Caucasian, Hispanic, or African American, these individuals were excluded from the analysis.
Predictor and Outcome Measures. The primary predictor was race/ethnicity determined by self-report at WIHS entry visit. We defined the African-American group as non-Hispanic African Americans. The Caucasian group was defined as non-Hispanic Caucasians. The Hispanic group was defined as Hispanic Caucasians, Hispanic African Americans, and other Hispanics. Our outcome of interest was primary liverrelated death, as determined by death certificate verification. We also reported data on all-cause mortality. Primary death certificate data were reviewed by two clinicians to determine cause of death. In some cases, there was supplemental information from medical record review, communication with the primary clinician, or patient families. Primary liver-related deaths included those resulting from hepatic decompensation or hepatocellular carcinoma, although most death certificates simply recorded ''hepatitis C'' as the primary cause of liver death, without further specification.
The following covariates were included in our survival analysis: age; substance abuse history, including intravenous (IV) drugs, non-IV drugs, tobacco, and alcohol; HIV-related factors, such as HIV RNA levels, CD4 count, and highly active antiretroviral therapy (HAART); liver-related factors, including HCV RNA levels, HCV genotype, HCV treatment history, and chronic hepatitis B virus (HBV); and comorbid factors, such as diabetes mellitus (DM), hypertension (HTN), body mass index (BMI), glomerular filtration rate (GFR), and cancer history.
Laboratory Assays. Plasma HIV RNA levels were measured using the NASBA/NuciSens HIV RNA assay (bioMerieux, Durham, NC) in laboratories certified by the NIH National Institute of Allergy and Infectious Diseases Virology Quality Assurance Certification Program. HCV and HBV serologies were performed using standard commercial assays and included hepatitis C Ab by EIA 3.0 (Ortho Clinical Diagnostics, Raritan, NJ) as well as hepatitis B surface antigen (HBsAg) (Abbott Laboratories, Abbott Park, IL). HCV RNA levels were measured by the COBAS Amplicor Monitor 2.0 assay (Roche Diagnostics, Branchburg, NJ), with a linear range of 600-700,000 IU/mL, or COBAS Taqman (Roche Diagnostics), with a linear range of 10-2.0 Â 10 8 IU/mL. Statistical Analysis. Patient characteristics were compared using chi-square tests, t tests, and KruskalWallis' tests, when appropriate. Cox's regression models were used to calculate the hazards ratios (HRs) and 95% confidence intervals (CIs) for factors associated with all-cause and liver-related mortality. All survival analyses used age as the time scale, with age at study entry treated as a left-truncation time to reflect the fact that only living women could be enrolled. This automatically accounts for the important influence of age on mortality risk and is a more biologically meaningful time scale than time since study enrolment. All variables that were measured repeatedly were analyzed as time-varying covariates, with the most recent value carried forward until a new measurement was made. The only non-time-varying covariates were race/ethnicity and HCV genotype, because these factors do not change over time. The final multivariate model was developed using forward selection of covariates, as well as inclusion of covariates with high biological plausibility of an association with death. A Fine-Gray competing-risks analysis, 16 as well as a survival analysis of non-liver-related death, was performed to assess the possibility that racial/ethnic differences in liver-related death could be attributed to a differential risk of nonliver-related death among racial/ethnic groups. All analyses were performed using STATA software (version 11.0; StataCorp LP, College Station, TX).
Results
We identified 794 women in the WIHS with confirmed CHC and HIV infection. Of these, 62.3% (495 of 794) were African American, 20% were Hispanic (159 of 794), and 17.7% (140 of 794) were Caucasian. Women were followed for up to 16 years, with a median follow-up of 8.9 years. The median follow-up for Caucasians, African Americans, and Hispanics was 9.0, 8.7, and 9.2 years, respectively. During this time, there were 438 deaths from all causes, including 49 liver-related deaths. Among primary causes of death, HIV/AIDS (36.9%) was the most common cause of death, followed by liver-related disease (11.2%) and homicides, suicides, and accidents (9.0% Compared to Hispanics and Caucasians, AfricanAmerican women were older at study entry and time of death. They were also more likely to have heavy alcohol and tobacco use, to be diagnosed with hypertension, and to be infected with HCV genotype 1. Compared to Hispanics and African Americans, Caucasian women were more likely to use IV drugs. There were no significant differences in median CD4 count, median HIV viral load, or HAART use between racial/ethnic groups. HCV treatment was uncommon, with similar percentages between racial/ethnic groups (Table 1) .
We first analyzed racial/ethnic differences in all-cause mortality, which was similar between racial/ethnic groups on both uni-and multivariate models (HRs for all comparisons: 0.82-1.03; log-rank test: P ¼ 0.8). These results contrasted markedly from our analysis of liver-related mortality. On univariate analysis, there was a trend toward lower risk of liver-related death among African Americans, compared to Caucasians (HR, 0.48; 95% CI: 0.23-1.03; P ¼ 0.058) and a statistically significantly lower risk of liver-related death among African Americans, compared to Hispanics (HR, 0.44; 95% CI: 0.22-0.87; P ¼ 0.019). On multivariate analysis, adjusted for CD4 count and HIV RNA levels, we observed even stronger racial/ethnic differences in liverrelated mortality, with an HR comparing African-American to Caucasian women of 0.41 (95% CI: 0.19-0.88; P ¼ 0.022) and an HR comparing African-American to Hispanic women of 0.38 (95% CI: 0.19-0.76; P ¼ 0.006). Liver-related mortality was similar between Caucasian and Hispanic coinfected women on uni-and multivariate analyses (Table 2 ). These associations are demonstrated graphically in an age-adjusted survival curve, with a log-rank test of P ¼ 0.032 (Fig. 1) .
Additional factors associated with liver-related mortality on univariate analysis included CD4 count (HR, 0.78 per 2-fold increase; 95% CI: 0.67-0.91; P ¼ 0.002) and HIV RNA level (HR, 1.47 per 10-fold increase; 95% CI: 1.17.0-1.9; P ¼ 0.001), although there was no significant association with HCV RNA levels (HR, 1.44; 95% CI: 0.94-2.2; P ¼ 0.09). On multivariate analysis, HIV RNA levels were associated with liver-related death (HR, 1.44; 95% CI: 1.11-1.9; P ¼ 0.006) ( Table 3) .
We also assessed liver-related mortality after adjusting for categories of factors that could affect risk of death. We continued to observe marked racial/ethnic differences in liver-related mortality after adjusting for cardiovascular risk factors, HIV immune control, and liver-related factors, suggesting that the observed racial/ethnic differences were not explained by these comorbid conditions (Table 4) .
Importantly, we performed a competing-risks analysis to determine whether the lower risk of liver-related mortality among African-American women was the result of African Americans dying at a higher rate from non-liver-related diseases, as compared to other racial/ethnic groups. In addition, we performed a survival analysis of non-liver-related mortality. The competing-risks analysis estimated that African-American HIV/HCV-coinfected women had a similar risk of non-liver-related mortality as other racial/ethnic groups, as did the survival analysis of non-liver-related mortality (HR, 1.01; 95% CI: 0.75 -1.36; P ¼ 0.95 versus Caucasians and HR, 1.18; 95% CI: 0.88-1.59; P ¼ 0.27 versus Hispanics). Therefore, African-American women had a lower risk of liver-related mortality, as compared to Hispanic and Caucasian coinfected women, independent of other causes of death. 
Discussion
In this large cohort of HIV/HCV-coinfected women, we investigated liver-related and all-cause mortality. We observed marked differences in liverrelated death between racial/ethnic groups, whereas allcause mortality was similar between African-American, Hispanic, and Caucasian coinfected women. African Americans were approximately 60% less likely to die from liver disease, as compared to Caucasian and Hispanic women. This relationship persisted after adjusting for an extensive list of covariates that could possibly affect risk of death.
A previous investigation of HIV/HCV-coinfected veterans identified important racial differences in allcause mortality, with significantly higher mortality among Caucasian coinfected males, compared to African Americans. Interestingly, these differences were not observed among HCV-monoinfected patients.
14 Unlike our study, the Veteran study was predominantly male and limited by its cross-sectional design, small number of Hispanic patients, and inability to investigate liverrelated death. Although the Veteran study did report important racial/ethnic differences in all-cause mortality among coinfected men, no previous data reflect liver-related mortality trends among coinfected populations or in HIV/HCV-coinfected women.
The reasons for the marked racial/ethnic differences in liver-related mortality in the current study certainly warrant further investigation. When we adjusted for many cofactors known to accelerate liver disease, such as HIV immune status, obesity, and alcohol use, we continued to observe significant differences between racial/ethnic groups. Although African Americans are less likely to spontaneously clear HCV, previous data do suggest that once chronically infected, African Americans tend to have less liver inflammation, as measured by alanine aminotransferase (ALT) levels and necroinflammatory scores on liver biopsy. 10 Sugimoto et al. also investigated T-cell response in patients with chronic HCV infection and found that African Americans had a significantly more-robust T-cell response than Caucasians, as well as higher platelet counts, lower bilirubin, and lower ALT levels. 17 These results were not due to alcohol use, gender differences, or 
